Their expression associated with clinically aggressive features, including PD-L1 expression in lung cancer, adverse pathological characteristics in prostate cancer, and poorer survival in HER2+ breast cancer with elevated PC2 levels. This evidence concerns the gene ERBB2 and breast carcinoma.